** Brokerage RBC Capital Markets raises PT on drugmaker Vertex Pharmaceutical VRTX.O to $420 from $408
** Brokerage suggests VRTX's cystic fibrosis treatment, Alyftrek, could be off to a "good start"
** The FDA approved VRTX's next-generation treatment for the genetic disease that affects lungs and other organs, in December 2024, after it showed non-inferiority to Vertex's Trikafta
** RBC says declines in Trifakta prescriptions leave open a good possibility that initial conversion to Alyftrek may be faster than expected, likely outpacing Street's $79 million sales expectations for Alyftrek in Q1
** Twenty-one of 33 brokerages rate the stock "buy" or higher, 12 "hold"; their median PT is $502.23, according to the data compiled by LSEG
** As of last close, VRTX has risen 16% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.